Free Trial
NASDAQ:CVKD

Cadrenal Therapeutics Q4 2024 Earnings Report

Cadrenal Therapeutics logo
$16.45 -0.05 (-0.30%)
Closing price 04:00 PM Eastern
Extended Trading
$16.53 +0.08 (+0.49%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cadrenal Therapeutics EPS Results

Actual EPS
-$2.74
Consensus EPS
-$1.71
Beat/Miss
Missed by -$1.03
One Year Ago EPS
N/A

Cadrenal Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cadrenal Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Cadrenal Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cadrenal Therapeutics Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
CVKD: Preparing for Phase 3 Trial of Tecarfarin…
See More Cadrenal Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email.

About Cadrenal Therapeutics

Cadrenal Therapeutics (NASDAQ:CVKD) operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

View Cadrenal Therapeutics Profile

More Earnings Resources from MarketBeat